China Pharmaceutical Sector Report 2020 4th Quarter
An EMIS Insights Industry ReportEMIS is an ISI Emerging Markets Group Company Date: January 2021
Pages: 62
Available in: English
In Q3 2020, manufacturing operations in China were completely resumed, and most of the pharmaceutical companies increased their production to meet the growing demand. The demand for COVID-19 related drugs, protective equipment and disinfection products continued to be very strong, while the improved access to clinics, hospitals and pharmacies drove the demand for other drugs. In this period, China’s API production volume rose by 89.5% y/y to 576,000 tonnes, and the output of TCMs increased by 45.7% y/y to 545,000 tonnes. During the quarter, China’s pharmaceutical sector witnessed a 9% y/y increase in revenue, which reached RMB 637.6bn, while its total profit rose by 20.8% y/y to RMB 91.9bn.
This report provides a complete and detailed analysis of the pharmaceutical sector for China. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.
What this report allows you to do:
- Understand the key elements at play in the pharmaceutical sector in China
- Access forecasts for growth in the sector
- View key data on production and sales for the sector in China
- Crystallise the forces both driving and restraining this sector in China
- Build a complete perspective on sector trade, investment and employment
- Understand the competitive landscape and who the major players are
- View M&A activity and major deals
- Gain an understanding of the regulatory environment for the sector in China
- Build a clear picture of trends and issues for sub-sectors (western medicine, traditional Chinese medicine)
See below for a complete table of report contents:
Email us at: emisstoresupport@emis.com